InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression o...
Q1 2026
May 6, 2026
FY 2025
Mar 20, 2026
Q4 2025
Q3 2025
Nov 10, 2025
Q2 2025
Aug 7, 2025